Literature DB >> 931549

HLA antigens in asbestosis.

H Matej, A Lange, R Smolik.   

Abstract

One hundred thirty-four workers in an asbestos factory who had been in contact with asbestos for about 20 years, were typed for 22 HLA antigens of the A and B loci. In this group, 22 workers were diagnosed as asbestosis patients on the basis of chest radiography and clinical findings; the remaining 112 were without signs of asbestosis. In the group of asbestosis patients an increase of B27 antigen was observed in comparison with the group without asbestosis (27-27% and 9-82% respectively). The relative risk = 3-44 is significant at the level of p less than 0-05. These results may indicate that a genetic factor, connected with HLA locus has influence on the development of asbestosis under conditions of contact with asbestos.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 931549

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  5 in total

1.  Histocompatibility antigens in a population based silicosis series.

Authors:  K Kreiss; J A Danilovs; L S Newman
Journal:  Br J Ind Med       Date:  1989-06

2.  Elevated binding activity of CD8+ cells with phytohaemagglutinin by asbestos fibre in vitro.

Authors:  K Kinugawa; F Hyodoh; A Andoh; A Ueki; H Tanaka; Y Mochizuki
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

3.  Immunogenetic factors as determinants of asbestosis.

Authors:  R Bégin; H Ménard; F Décarie; A St-Sauveur
Journal:  Lung       Date:  1987       Impact factor: 2.584

4.  The histocompatibility antigen in asbestos related disease.

Authors:  N Al Jarad; S Uthayakumar; E J Buckland; T S Green; J Ord; A C Newland; R M Rudd
Journal:  Br J Ind Med       Date:  1992-12

Review 5.  Trends and perspectives of the biological prophylaxis of silicosis.

Authors:  B A Katsnelson; E V Polzik; K I Morosova; L I Privalova; N S Kislitsina; V S Kasantsev
Journal:  Environ Health Perspect       Date:  1989-07       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.